In a high-stakes hearing before the U.S. Supreme Court on Tuesday, the justices considered a challenge to the Food and Drug Administration's regulation of mifepristone, the first pill in a two-drug regimen for medication abortion, which is the most common method of abortion in the country. This marks the first major reproductive rights case before the high court since Roe v. Wade was overturned in 2022. A decision is expected by the end of June.
As per reports from ABC News, the Alliance for Hippocratic Medicine, a group of anti-abortion medical organizations, challenged the FDA's approval of mifepristone. They argued that the FDA's decisions in 2016 and 2021, which relaxed restrictions on the drug, were unsound. The group claims that mifepristone is not safe and that the FDA didn't adequately study it before approval.
